
    
      Subjects will receive product as described in the sipuleucel-T approved label. The registry
      will be strictly observational and thus no additional clinical visits or laboratory tests
      will be conducted beyond normal clinical practice. Investigators will be asked to record
      information that becomes available in the normal course of clinical management.
    
  